interferon-alfa
Jump to navigation
Jump to search
Indications
- treatment of hepatitis B
- FDA-approved adjuvant therapy for malignant melanoma
- condyloma accuminata[3]
- laryngeal papillomatosis
- hemangioma
- Kaposi's sarcoma
- mycosis fungoides-Sezary syndrome
- Hairy cell leukemia
- multiple myeloma[3]
Contraindications
- active autoimmune disorder
- decompensated cirrhosis
- major depression
Adverse effects
- hypothyroidism (10%)
- heart failure from previous myocardial infarction during treatment (rare)[2]
Mechanism of action
- IFN-alfa appears to affect the STAT1:STAT3 ratio in malignant melanoma, improving recurrence-free survival
- STAT1 is a tumor suppressor gene
- STAT3 is a mediator of tumor progression
- STAT1 increases & pSTAT3 decreases in nevi during maturation of melanocytes
More general terms
More specific terms
Additional terms
References
- ↑ Wang W et al. STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: Dose-response effects of systemic IFN therapy. J Invest Dermatol 2008 Aug; 128:1997. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18305569
- ↑ 2.0 2.1 Medical Knowledge Self Assessment Program (MKSAP) 14, 17. American College of Physicians, Philadelphia 2006, 2015
- ↑ 3.0 3.1 3.2 Deprecated Reference